My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer : Episode 7

Video

May 1, 2023

Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

Author(s):

Andrew J. Armstrong, MD,Matthew Manning, MD

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

EP: 1.The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP: 2.Approved Treatment Options for Patients with mCRPC

EP: 3.Patient Profile: A 78-Year-Old Man with mCRPC

EP: 4.Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

EP: 5.Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

EP: 6.Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

Now Viewing

EP: 7.Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

EP: 8.Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

EP: 9.Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

EP: 10.Closing Thoughts on the Future of mCRPC Treatment

Related Content

December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

December 5th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer